Financing - September 27, 2016
Dilafor raises SEK 51 million
Karolinska Development announces that its portfolio company Dilafor, a drug development company focusing on the development of tafoxiparin for obstetric indications, has successfully completed a financing round raising SEK 51 million (US$5.9 million) from new and existing investors. The new investors include Lee’s Healthcare Industry Fund, Rosetta Capital IV and Pila AB. Dilafor’s largest existing […]
Agreement - October 9, 2014
Dilafor signs agreement with Opocrin
Swedish Dilafor AB and Italian Opocrin S.p.A. have entered into a commercial supply and partnership agreement. In the agreement, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for Dilafor’s candidate drug tafoxiparin for the European, US, CIS and Japanese markets. Opocrin will also supply manufacturing services during […]
Agreement - February 24, 2014
Dilafor in new license agreement
Dilafor AB, part of Karolinska Development’s portfolio of companies, has signed an agreement with Hong Kong-based biopharmaceutical firm. According to the agreement, Dilafor grants to Lee’s Pharmaceutical the right to manufacture, develop and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau and Taiwan. Pursuant to the terms of the agreement, Dilafor and Lee’s […]
